Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
Elastic
ESTC
|
$348M |
| 2 |
Mercado Libre
MELI
|
$296M |
| 3 |
Nu Holdings
NU
|
$254M |
| 4 |
Roblox
RBLX
|
$219M |
| 5 |
Shopify
SHOP
|
$201M |
Top Sells
| 1 |
Albemarle
ALB
|
$185M |
| 2 |
Illumina
ILMN
|
$176M |
| 3 |
Li Auto
LI
|
$162M |
| 4 |
Trade Desk
TTD
|
$145M |
| 5 |
Ferrari
RACE
|
$138M |
Sector Composition
| 1 | Consumer Discretionary | 29% |
| 2 | Healthcare | 24.31% |
| 3 | Technology | 17.32% |
| 4 | Communication Services | 11.22% |
| 5 | Financials | 6.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
Charles River Laboratories
CRL
$8.07B
| $14.2M | 0.01% |
71,899
+56,103
| +355% | +$11M |
|
202
StoneCo
STNE
$4.63B
| $13.8M | 0.01% |
1,443,026
+34,884
| +2% | +$332K |
|
203
Masimo
MASI
$8B
| $13.2M | 0.01% |
93,634
+4,162
| +5% | +$587K |
|
204
Tandem Diabetes Care
TNDM
$850M
| $12.6M | 0.01% |
263,084
-43,139
| -14% | -$2.06M |
|
205
Burford Capital
BUR
$2.92B
| $12.1M | 0.01% |
1,623,145
-51,362
| -3% | -$382K |
|
206
Stratasys
SSYS
$871M
| $11.6M | 0.01% |
805,904
-64,551
| -7% | -$930K |
|
207
TJX Companies
TJX
$155B
| $11M | 0.01% |
177,210
-4,076
| -2% | -$253K |
|
208
CEVA Inc
CEVA
$543M
| $10.8M | 0.01% |
410,994
-68,478
| -14% | -$1.8M |
|
|
CELL
209
DELISTED
PhenomeX Inc. Common Stock
CELL
| $10.6M | 0.01% |
3,718,200
+39,216
| +1% | +$112K |
|
210
QuantumScape
QS
$4.44B
| $10.6M | 0.01% |
1,262,341
+346,060
| +38% | +$2.91M |
|
211
Digimarc
DMRC
$181M
| $10.6M | 0.01% |
780,637
-47,129
| -6% | -$639K |
|
|
AKLI
212
DELISTED
Akili, Inc. Common Stock
AKLI
| $10.5M | 0.01% |
+4,665,795
| New | +$10.5M |
|
213
LivePerson
LPSN
$89.9M
| $10.5M | 0.01% |
1,117,812
-63,859
| -5% | -$602K |
|
214
Sutro Biopharma
STRO
$89.9M
| $10.4M | 0.01% |
1,868,615
+3,435
| +0.2% | +$19.1K |
|
215
Cardlytics
CDLX
$49.6M
| $10.3M | 0.01% |
1,098,968
-41,943
| -4% | -$394K |
|
216
Butterfly Network
BFLY
$393M
| $9.77M | 0.01% |
2,078,788
+37,819
| +2% | +$178K |
|
217
Visa
V
$666B
| $9.33M | 0.01% |
52,499
| – | – |
|
218
Ascendis Pharma
ASND
$12.5B
| $9.14M | 0.01% |
88,497
+2,697
| +3% | +$279K |
|
|
KDNY
219
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $9.13M | 0.01% |
464,314
-40,511
| -8% | -$796K |
|
220
Sherwin-Williams
SHW
$92.9B
| $9.1M | 0.01% |
44,453
| – | – |
|
221
EverQuote
EVER
$860M
| $9.07M | 0.01% |
1,330,065
-47,261
| -3% | -$322K |
|
222
Relay Therapeutics
RLAY
$710M
| $9.05M | 0.01% |
404,620
+184,998
| +84% | +$4.14M |
|
223
Zillow
ZG
$20.5B
| $9.05M | 0.01% |
316,059
-28,418
| -8% | -$814K |
|
224
XP
XP
$9.96B
| $8.82M | 0.01% |
464,136
+6,192
| +1% | +$118K |
|
225
Bumble
BMBL
$697M
| $8.6M | 0.01% |
400,000
| – | – |
|